• Andersson-Ellstrom, A., Dillner, J., Hagmar, B., Schiller, J., Sapp, M., Forssman, L. and Milsom, I., Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex. Transm. Dis., 23, 234238 (1996).
  • Bosch, F. X. and 16 others, Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol. Biomarkers Prev., 2, 415422 (1993).
  • Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R. and Shah, K. V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group (see comments). J. nat. Cancer Inst., 87, 796802 (1995).
  • Dillner, J., Serology of human papillomavirus. Cancer J., 264269 (1995).
  • Dillner, J., Kallings, I., Brihmer, C., Sikstøm, B., Koskela, P., Lehtinen, M., Schiller, J. T., Sapp, M. and Mårdh, P. A., Seropositivity to human papillomavirus types 16, 18, or 33 Capsids and to Chlamydia trachomatis are markers of sexual behavior. J. infect. Dis., 173, 13948 (1996).
  • Dillner, J., Wiklund, F., Lenner, P., Eklund, C., Frederiksson Shanazarian, V., Schiller, J. T., Hibma, M., Hallmans, G. and Stendahl, U., Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int. J. Cancer, 60, 377382 (1995).
  • Evander, M., Edlund, K., Gustafsson, A., Jonsson, M., Karlsson, R., Rylander, E. and Wadell, G., Human papillomavirus infection is transient in young women: a population-based cohort study. J. infect. Dis., 171, 10261030 (1995).
  • Gjoen, K., Siebke, J. C., Flikke, M., Hager, R., Ertzeid, G., Halsos, A., Ekgren, J., Norling, B., Grinde, B. and Orstavik, I., Genital human-papilloma-virus infection in Oslo studied by dot-blot DNA hybridization and the polymerase chain reaction. J. med. Virol., 34, 159164 (1991).
  • Heino, P., Eklund, C., Fredriksson Shanazarian, V., Goldman, S., Schiller, J. T. and Dillner, J., Association of serum immunoglobulin G antibodies against human papillomavirus-type-16 capsids with anal epidermoid carcinoma (see comments). J. nat. Cancer Inst., 87, 437440 (1995).
  • Hildesheim, A., Schiffman, M. H., Gravitt, P. E., Glass, A. G., Greer, C. E., Zhang, T., Scott, D. R., Rush, B. B., Lawler, P., Sherman, M. E., Kurman, R. J. and Manos, M. M., Persistence of type-specific human papillomavirus infection among cytologically normal women (see comments). J. infect. Dis., 169, 235240 (1984).
  • Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R. and Schiller, J. T., A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16 (see comments). J. nat. Cancer Inst., 86, 494499 (1994).
  • Kjaer, S. K. and 12 others, Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)—a second look. Brit. J. Cancer, 67, 830837 (1993).
  • Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., Derouen, T. A., Galloway, D. A., Vernon, D. and Kiviat, N. B., A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. New Engl. J. Med., 327, 12721278 (1992).
  • Lehtinen, M., Dillner, J., Knekt, P., Luostarinen, T., Aromaa, A., Kirnbauer, R., Koskela, P., Paavonen, J., Peto, R., Schiller, J. T. and Hakama, M., Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study. Brit. med. J., 312, 537539 (1996).
  • Muñoz, N. and 17 others, The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int. J. Cancer, 52, 743749 (1992).
  • Nonnenmacher, B., Hubbert, N. L., Kirnbauer, R., Shah, K. V., Muñoz, N., Bosch, F. X., De Sanjose, S., Viscidi, R., Lowy, D. R. and Schiller, J. T., Serologic response to human papillomavirus-type-16(HPV-16)-virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial-neoplasia-grade-III patients and controls from Colombia and Spain. J. infect. Dis., 172, 1924 (1995).
  • Olsen, A. O., Gjoen, K., Sauer, T., Orstavik, I., Naess, O., Kierulf, K., Sponland, G. and Magnus, P., Human papillomavirus and cervical intraepithelial neoplasia grade II-III: a population-based case-control study. Int. J. Cancer, 61, 312315 (1995).
  • Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., Stanton, C. K. and Manos, M. M., Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia [see comments]. J. nat. Cancer Inst., 85, 958964 (1993).
  • Schneider, A., Kirchhoff, T., Meinhardt, G. and Gissmann, L., Repeated evaluation of human papillomavirus 16 status in cervical swabs of young women with a history of normal Papanicolaou smears. Obstet. Gynecol., 79, 683688 (1992).
  • SPSS Inc., SPSS for Windows: Advanced Statistics, Release 60, Chicago, IL (1993).
  • Wideroff, L., and 15 others, Evaluation of seroreactivity to human papillomavirus-type-16-virus-like particles in an incident case-control study of cervical neoplasia. J. infect. Dis., 14251430 (1995).
  • Wikstrom, A., van Doornum, G. J., Quint, W. G., Schiller, J. T. and Dillner, J., Identification of human papillomavirus seroconversions. J. gen. Virol., 76, 529539 (1995).